
Zacks Small-Cap Research (Zacks SCR) has raised its target price for BioStem Technologies, a developer of perinatal tissue-based therapies, believing the stock should trade at double its current market price. This comes after the company’s third-quarter financial results, which beat Wall Street expectations. Details Zacks SCR values BioStem Technologies stock…